{"id":12172,"date":"2013-11-01T12:02:47","date_gmt":"2013-11-01T16:02:47","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=12172"},"modified":"2013-11-01T12:02:47","modified_gmt":"2013-11-01T16:02:47","slug":"bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172","title":{"rendered":"Bad News for Amarin Corporation plc (NASDAQ:AMRN) at NASDAQ, Stalemate till approval"},"content":{"rendered":"<p style=\"text-align: justify;\">Amarin Corporation plc (NASDAQ:AMRN) was barred from trading at the NASDAQ exchange till the company comes clean for its new fish\u2014oil drug Vascepa. While AMRN has requested the US FDA body to approve the marketing of its new product, the FDA has dispatched a special committee to review this request even as the company waits.<\/p>\n<p style=\"text-align: justify;\">This biopharmaceutical company has hopes that the FDA will approve further expansion of its fish-oil drug Vascepa for use by heart patients. The drug is used mostly for hyperglyceridemic patients to help them lower the levels of triglycerides from their blood. The FDA approval for the drug also states that it was approved to be used for hyperglyceridemic patients only. It is expected that the FDA\u2019s special committee known as the Endocrinologic and Metabolic Drugs Advisory Committee will meet soon and take action on this matter.<\/p>\n<p style=\"text-align: justify;\">It is hoped that the FDA will release its direct verdict on the expansion of the use of this drug by the end of this year. For this particular assessment the FDA is looking at the ability of this drug to provide any noticeable comfort to heart patients although there have been several studies which indicate that triglyceride levels are brought down by as much as 20%. Recent studies by different sources have however revealed that the lowering of triglyceride levels and cholesterol levels don\u2019t really have much of an impact when it comes to heart and heart related diseases. This could very well turn out to be bad news for the company and Vascepa as the company may have to wait for a little longer to get the results that it wants to be able to widen the scope of Vascepa. The current share values for Amarin Corporation stand at $5.17.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Amarin Corporation plc (NASDAQ:AMRN) was barred from trading at the NASDAQ exchange till the company comes clean for its new fish\u2014oil drug Vascepa. While AMRN [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":7931,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[3628,4033,3313],"stock_ticker":[],"class_list":["post-12172","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-amarin-corporation-plc","tag-amarin-corporation-plc-nasdaqamrn","tag-nasdaqamrn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bad News for Amarin Corporation plc (NASDAQ:AMRN) at NASDAQ, Stalemate till approval - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bad News for Amarin Corporation plc (NASDAQ:AMRN) at NASDAQ, Stalemate till approval - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Amarin Corporation plc (NASDAQ:AMRN) was barred from trading at the NASDAQ exchange till the company comes clean for its new fish\u2014oil drug Vascepa. While AMRN [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-11-01T16:02:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-11.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Brendan Byrne\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brendan Byrne\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172\"},\"author\":{\"name\":\"Brendan Byrne\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\"},\"headline\":\"Bad News for Amarin Corporation plc (NASDAQ:AMRN) at NASDAQ, Stalemate till approval\",\"datePublished\":\"2013-11-01T16:02:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172\"},\"wordCount\":308,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-11.jpg\",\"keywords\":[\"Amarin Corporation plc\",\"Amarin Corporation plc (NASDAQ:AMRN)\",\"NASDAQ:AMRN\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172\",\"name\":\"Bad News for Amarin Corporation plc (NASDAQ:AMRN) at NASDAQ, Stalemate till approval - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-11.jpg\",\"datePublished\":\"2013-11-01T16:02:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-11.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-11.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bad News for Amarin Corporation plc (NASDAQ:AMRN) at NASDAQ, Stalemate till approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\",\"name\":\"Brendan Byrne\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"caption\":\"Brendan Byrne\"},\"description\":\"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bad News for Amarin Corporation plc (NASDAQ:AMRN) at NASDAQ, Stalemate till approval - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172","og_locale":"en_US","og_type":"article","og_title":"Bad News for Amarin Corporation plc (NASDAQ:AMRN) at NASDAQ, Stalemate till approval - Wall Street PR","og_description":"Amarin Corporation plc (NASDAQ:AMRN) was barred from trading at the NASDAQ exchange till the company comes clean for its new fish\u2014oil drug Vascepa. While AMRN [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-11-01T16:02:47+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-11.jpg","type":"image\/jpeg"}],"author":"Brendan Byrne","twitter_misc":{"Written by":"Brendan Byrne","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172"},"author":{"name":"Brendan Byrne","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511"},"headline":"Bad News for Amarin Corporation plc (NASDAQ:AMRN) at NASDAQ, Stalemate till approval","datePublished":"2013-11-01T16:02:47+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172"},"wordCount":308,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-11.jpg","keywords":["Amarin Corporation plc","Amarin Corporation plc (NASDAQ:AMRN)","NASDAQ:AMRN"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172","url":"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172","name":"Bad News for Amarin Corporation plc (NASDAQ:AMRN) at NASDAQ, Stalemate till approval - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-11.jpg","datePublished":"2013-11-01T16:02:47+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-11.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/06\/pharma-11.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/bad-news-for-amarin-corporation-plc-nasdaqamrn-at-nasdaq-stalemate-till-approval-12172#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Bad News for Amarin Corporation plc (NASDAQ:AMRN) at NASDAQ, Stalemate till approval"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511","name":"Brendan Byrne","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","caption":"Brendan Byrne"},"description":"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/12172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=12172"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/12172\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/7931"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=12172"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=12172"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=12172"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=12172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}